Key facts
- It has raised $6.0M; the latest was Seed Round ($6.0M) in Oct 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for NeuroDiscovery AI
- ·The full record, as it builds
Funding rounds
No funding rounds for NeuroDiscovery AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeuroDiscovery AI
Developer of a HIPAA-compliant neurology platform designed to transform fragmented clinical data into actionable insights for research and care advancement. The company offers AI-driven patient matching, real-time analytics, neuroimaging interpretation, and EHR-embedded intelligence, enabling biopharma sponsors, providers, and CROs to accelerate recruitment, improve trial outcomes, and reduce operational costs.
- Sector
- Healthcare
- HQ
- Alpharetta, GA, United States
- Founded
- 2023
- Employees
- 55
- Website
- neurodiscovery.ai/
- Ownership
- Privately Held (backing)
NeuroDiscovery AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroDiscovery AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroDiscovery AI in its N-PORT filings yet. We sweep new filings monthly.